LC
CLDX icon

Lindbrook Capital’s Celldex Therapeutics CLDX Stock Holding History

Lindbrook Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$3.81K Sell
210
-62
-23% -$1.39K ﹤0.01% 2066
2024
Q4 		$6.87K Buy
272
+107
+65% +$2.91K ﹤0.01% 1836
2024
Q3 		$5.61K Buy
165
+10
+6% +$381 ﹤0.01% 1968
2024
Q2 		$5.74K Hold
155
– – ﹤0.01% 1934
2024
Q1 		$6.5K Hold
155
– – ﹤0.01% 1780
2023
Q4 		$6.15K Buy
+155
New +$4.56K ﹤0.01% 1775
2023
Q3 		– Sell
-54
Closed -$1.69K – 2707
2023
Q2 		$1.83K Buy
54
+11
+26% +$371 ﹤0.01% 2178
2023
Q1 		$1.55K Sell
43
-36
-46% -$1.55K ﹤0.01% 2344
2022
Q4 		$3.52K Buy
79
+76
+2,533% +$2.71K ﹤0.01% 1983
2022
Q3 		$0 Sell
3
-6
-67% -$184 ﹤0.01% 2653
2022
Q2 		$0 Sell
9
-43
-83% -$1.25K ﹤0.01% 2520
2022
Q1 		$2K Buy
+52
New +$1.66K ﹤0.01% 1962
2021
Q4 		– Sell
-990
Closed -$53K – 2087
2021
Q3 		$53K Buy
+990
New +$46.5K 0.01% 420
2021
Q2 		– Sell
-1,000
Closed -$21K – 1920
2021
Q1 		$21K Buy
+1,000
New +$23K ﹤0.01% 736
2020
Q3 		– Sell
-1,618
Closed -$21K – 1757
2020
Q2 		$21K Buy
+1,618
New +$7.17K 0.01% 587

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lindbrook Capital's CLDX Position: Q1 2025 in Review

Lindbrook Capital reduced its Celldex Therapeutics (CLDX) stake by 23% in Q1 2025, selling an estimated $1.39K and leaving 210 shares worth $3.81K. The position accounts for ﹤0.01% of the portfolio, ranked #2066.

Lindbrook Capital first reported a position in CLDX in Q2 2020 and has held it in 15 quarters since. The position peaked at $53K in Q3 2021. 171 funds tracked by Wall St. Rank hold CLDX as of Q1 2025.

  • Lindbrook Capital held 210 shares of Celldex Therapeutics worth $3.81K as of Q1 2025.
  • Lindbrook Capital sold 62 Celldex Therapeutics shares in Q1 2025, an estimated $1.39K.
  • Celldex Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2066 holding.
  • Lindbrook Capital first reported a position in Celldex Therapeutics in Q2 2020 and has held it in 15 quarters since.
  • Lindbrook Capital's Celldex Therapeutics position peaked at $53K in Q3 2021.
  • 171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.